The results validate conclusions drawn by Bagli et al. [one], who performed a research that provided ten patients diagnosed with CRAO who received HBOT. As well as acquiring 20 sessions of HBOT, oral acetazolamide and topical beta-blockers were being administered on the patients on the earliest prob